TECX TECTONIC THERAPEUTIC INC.

Tectonic Therapeutic to Participate in December Investor Conferences

Tectonic Therapeutic to Participate in December Investor Conferences

WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025.

Piper Sandler 37th Annual Healthcare Conference

Date:

Time:

Location:

Format:

Presenters:

Webcast:
December 2, 2025

3:30 PM EST

New York, NY

Fireside Chat

Alise Reicin, MD, President and Chief Executive Officer



Evercore 8
th Annual Healthcare Conference

Date:

Location:

Format:
December 3, 2025

Miami, FL

Investor Meetings



The live fireside chat can also be accessed under “” on the Investors section of the Tectonic website at . A replay of the webcast will be available on the Company’s website for approximately 90 days.

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.

About Tectonic

is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit  and follow us on .



Contacts:

Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
 

Media:
Kathryn Morris
The Yates Network
(914) 204-6412
 
EN
01/12/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TECTONIC THERAPEUTIC INC.

 PRESS RELEASE

Tectonic Therapeutic to Participate in December Investor Conferences

Tectonic Therapeutic to Participate in December Investor Conferences WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Presenters:Webcast:December 2, 20253:30 PM ESTNew Yo...

 PRESS RELEASE

Tectonic Therapeutic Announces Third Quarter 2025 Financial Results an...

Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”)Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1’2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”)TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety ...

 PRESS RELEASE

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Par...

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45’s addressable Group 2 PH patient population to PH...

 PRESS RELEASE

Tectonic Therapeutic to Participate in September Investor Conferences

Tectonic Therapeutic to Participate in September Investor Conferences WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings   ...

 PRESS RELEASE

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results a...

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Grou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch